Johnson & Johnson has reached an agreement with Shockwave Medical, Inc. to “acquire all outstanding shares of Shockwave” in a deal with an “enterprise value of approximately $13.1 billion.”
Shockwave represents a significant acquisition for Johnson & Johnson in the cardiovascular intervention space. Shockwave is “a leading, first-to-market provider of innovative intravascular lithotripsy (IVL) technology for the treatment of calcified CAD [coronary artery disease] and PAD [peripheral artery disease]. IVL is a minimally invasive, catheter-based treatment for calcified arterial lesions, which can reduce blood flow and cause pain or heart attack. IVL helps restore blood flow by cracking calcium lesions using sonic pressure waves and is used in both CAD and PAD, often in combination with stenting. Shockwave offers the only commercially available IVL technology and has safely, simply, and effectively treated approximately 400,000 patients globally.”
Johnson & Johnson already includes Abiomed, “a leader in heart recovery, and more recently Laminar, an innovator in left atrial appendage elimination for patients with non-valvular atrial fibrillation (AFib)” in their portfolio.
IVL is “the only technology that can treat both intimal and medial calcification,” now added to Johnson & Johnson’s MedTech portfolio. Adding these compatibilities to Johnson & Johnson’s infrastructure should “provide numerous opportunities to accelerate the adoption of these segment-leading technologies to patients in need.”
Johnson & Johnson’s website has the release.
